vs
Side-by-side financial comparison of Cytosorbents Corp (CTSO) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $9.2M, roughly 1.0× Cytosorbents Corp). Cytosorbents Corp runs the higher net margin — -59.5% vs -234.3%, a 174.8% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 0.9%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 1.3%).
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
CTSO vs FHTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $9.2M |
| Net Profit | $-5.5M | $-21.7M |
| Gross Margin | 73.7% | — |
| Operating Margin | -47.5% | -258.2% |
| Net Margin | -59.5% | -234.3% |
| Revenue YoY | 0.9% | 223.8% |
| Net Profit YoY | 27.4% | -11.1% |
| EPS (diluted) | $-0.09 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $9.2M | ||
| Q3 25 | $9.5M | $8.2M | ||
| Q2 25 | $9.6M | $7.6M | ||
| Q1 25 | $8.7M | $6.0M | ||
| Q4 24 | $9.2M | $2.9M | ||
| Q3 24 | $8.6M | $7.8M | ||
| Q2 24 | $8.8M | $6.9M | ||
| Q1 24 | $9.0M | $5.0M |
| Q4 25 | $-5.5M | $-21.7M | ||
| Q3 25 | $-3.2M | $-15.8M | ||
| Q2 25 | $1.9M | $-17.9M | ||
| Q1 25 | $-1.5M | $-18.8M | ||
| Q4 24 | $-7.6M | $-19.5M | ||
| Q3 24 | $-2.8M | $-19.1M | ||
| Q2 24 | $-4.3M | $-23.0M | ||
| Q1 24 | $-6.1M | $-25.0M |
| Q4 25 | 73.7% | — | ||
| Q3 25 | 70.3% | — | ||
| Q2 25 | 70.9% | — | ||
| Q1 25 | 71.1% | — | ||
| Q4 24 | 68.4% | — | ||
| Q3 24 | 61.0% | — | ||
| Q2 24 | 73.5% | — | ||
| Q1 24 | 76.5% | — |
| Q4 25 | -47.5% | -258.2% | ||
| Q3 25 | -30.2% | -226.9% | ||
| Q2 25 | -37.6% | -279.2% | ||
| Q1 25 | -44.5% | -385.0% | ||
| Q4 24 | -37.1% | -840.5% | ||
| Q3 24 | -56.1% | -305.5% | ||
| Q2 24 | -40.4% | -386.6% | ||
| Q1 24 | -51.8% | -558.3% |
| Q4 25 | -59.5% | -234.3% | ||
| Q3 25 | -33.4% | -194.4% | ||
| Q2 25 | 20.2% | -237.3% | ||
| Q1 25 | -16.9% | -316.4% | ||
| Q4 24 | -82.7% | -682.9% | ||
| Q3 24 | -32.1% | -244.9% | ||
| Q2 24 | -48.6% | -333.6% | ||
| Q1 24 | -67.7% | -495.4% |
| Q4 25 | $-0.09 | $-0.35 | ||
| Q3 25 | $-0.05 | $-0.25 | ||
| Q2 25 | $0.03 | $-0.28 | ||
| Q1 25 | $-0.02 | $-0.30 | ||
| Q4 24 | $-0.14 | $-0.23 | ||
| Q3 24 | $-0.05 | $-0.31 | ||
| Q2 24 | $-0.08 | $-0.45 | ||
| Q1 24 | $-0.11 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.2M | $80.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9M | $-108.5M |
| Total Assets | $44.2M | $198.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.2M | $80.9M | ||
| Q3 25 | $7.5M | $89.3M | ||
| Q2 25 | $10.2M | $72.6M | ||
| Q1 25 | $11.6M | $61.0M | ||
| Q4 24 | $3.3M | $55.5M | ||
| Q3 24 | $5.7M | $57.7M | ||
| Q2 24 | $8.5M | $138.9M | ||
| Q1 24 | $8.6M | $79.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $4.4M | — |
| Q4 25 | $5.9M | $-108.5M | ||
| Q3 25 | $9.0M | $-89.7M | ||
| Q2 25 | $11.6M | $-76.7M | ||
| Q1 25 | $14.5M | $-61.7M | ||
| Q4 24 | $11.1M | $-45.5M | ||
| Q3 24 | $13.4M | $-28.3M | ||
| Q2 24 | $17.4M | $-14.3M | ||
| Q1 24 | $19.6M | $-97.5M |
| Q4 25 | $44.2M | $198.1M | ||
| Q3 25 | $45.8M | $205.0M | ||
| Q2 25 | $48.0M | $226.2M | ||
| Q1 25 | $50.8M | $258.7M | ||
| Q4 24 | $47.4M | $284.0M | ||
| Q3 24 | $47.8M | $308.4M | ||
| Q2 24 | $53.4M | $328.6M | ||
| Q1 24 | $47.1M | $255.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.23× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $-22.3M |
| Free Cash FlowOCF − Capex | $-4.9M | — |
| FCF MarginFCF / Revenue | -53.4% | — |
| Capex IntensityCapex / Revenue | 1.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.8M | $-22.3M | ||
| Q3 25 | $-2.6M | $-18.9M | ||
| Q2 25 | $-1.5M | $-21.0M | ||
| Q1 25 | $-3.5M | $-24.0M | ||
| Q4 24 | $-2.3M | $-24.5M | ||
| Q3 24 | $-2.5M | $-21.0M | ||
| Q2 24 | $-4.8M | $-25.5M | ||
| Q1 24 | $-4.8M | $-29.3M |
| Q4 25 | $-4.9M | — | ||
| Q3 25 | $-2.6M | — | ||
| Q2 25 | $-1.5M | $-21.0M | ||
| Q1 25 | $-3.5M | $-24.0M | ||
| Q4 24 | $-2.4M | $-25.0M | ||
| Q3 24 | $-2.6M | $-21.3M | ||
| Q2 24 | $-4.8M | $-25.6M | ||
| Q1 24 | $-4.9M | $-29.4M |
| Q4 25 | -53.4% | — | ||
| Q3 25 | -27.3% | — | ||
| Q2 25 | -16.1% | -278.2% | ||
| Q1 25 | -39.7% | -403.2% | ||
| Q4 24 | -26.3% | -875.3% | ||
| Q3 24 | -30.4% | -273.0% | ||
| Q2 24 | -54.4% | -371.0% | ||
| Q1 24 | -54.2% | -583.1% |
| Q4 25 | 1.2% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 0.4% | 0.3% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.8% | 16.8% | ||
| Q3 24 | 1.8% | 4.0% | ||
| Q2 24 | 0.2% | 0.2% | ||
| Q1 24 | 0.5% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.78× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
FHTX
Segment breakdown not available.
